Phase 1 Study of Anti-TGFβRII Monoclonal Antibody IMC-TR1 (LY3022859) in Patients With Advanced Solid Tumors That Have Failed Standard Therapy or for Which No Standard is Available

Trial Profile

Phase 1 Study of Anti-TGFβRII Monoclonal Antibody IMC-TR1 (LY3022859) in Patients With Advanced Solid Tumors That Have Failed Standard Therapy or for Which No Standard is Available

Discontinued
Phase of Trial: Phase I

Latest Information Update: 01 Apr 2017

At a glance

  • Drugs IMC TR1 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Eli Lilly; ImClone Systems
  • Most Recent Events

    • 28 Oct 2014 Planned End Date changed from 1 Mar 2015 to 1 Oct 2014, according to ClinicalTrials.gov
    • 28 Oct 2014 Planned primary completion date changed from 1 Mar 2015 to 1 Oct 2014, according to ClinicalTrials.gov
    • 09 Sep 2014 Planned End Date changed from 1 Feb 2015 to 1 Mar 2015 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top